PSMA PET for Staging Bone Oligometastatic Prostate Cancer: A Closer Look

PSMA PET imaging offers staging advantages over conventional imaging in osseous oligometastatic prostate cancer, potentially reshaping treatment decisions — though exact performance figures not reported in source.

• Trade-press commentary examining the role of PSMA PET in detecting and staging bone oligometastatic prostate cancer; no primary study data or patient cohort reported in the snippet.
• PSMA PET is known to outperform conventional bone scan and CT for detection of nodal and osseous metastases, with implications for defining oligometastatic disease boundaries (exact figures not reported in source).
• As a trade-news piece without an original dataset, claims should be interpreted as expert perspective or synthesis rather than new primary evidence.

RadPigeon summaries are original and for information only. They are not clinical advice.